In Today’s NeuroPulse, the neurology sector advanced across multiple fronts, with fresh capital flowing into mental health drug development, early clinical milestones reached in brain cancer and neurodegeneration, and regulators extending approvals that lower risk in pediatric imaging and neuromodulation. From nine-figure biotech launches and oversubscribed neurotech seed rounds to first-in-human dosing, personalized spinal cord stimulation research, and data-driven partnerships targeting intracellular CNS biology, the day’s developments reflect a field moving beyond experimentation toward execution. Together, these updates highlight how neuroscience innovation is increasingly anchored in validated mechanisms, clearer regulatory pathways, and platforms designed to translate complexity into clinical impact.
Soin Neuroscience and BIOTRONIK Neuro Partner on Personalized Spinal Cord Stimulation
Pulse:
- Soin Neuroscience and BIOTRONIK Neuro announced a research collaboration to advance personalized spinal cord stimulation tuning using proprietary waveform technologies.
- The initiative will evaluate adaptive programming strategies and novel waveforms designed to reduce variability in patient response to SCS therapy.
- BIOTRONIK’s Prospera SCS System provides a flexible platform for iterative optimization and remote programming, supporting next-generation neuromodulation paradigms.
- The collaboration reflects a broader industry shift toward data-driven, patient-specific neuromodulation rather than fixed stimulation protocols.
Mercury Bio and Meta-Flux Partner to Advance Large-Molecule CNS Therapies in Parkinson’s and Alzheimer’s
Pulse:
- Mercury Bio and Meta-Flux announced a strategic collaboration aimed at accelerating the development of large-molecule therapeutics for neurodegenerative diseases, starting with Parkinson’s and Alzheimer’s, areas where intracellular pathology remains largely unaddressed by existing drugs.
- The partnership combines Mercury Bio’s patented yeast extracellular vesicle (yEV™) delivery platform, engineered to transport proteins, RNA, and other large biologics into neurons and release them directly into the cytoplasm, thereby bypassing endosomal degradation and the blood–brain barrier.
- Meta-Flux contributes its disease-scale computational modeling platform, integrating multi-omics data and systems biology to simulate pathway dynamics and cellular state changes, enabling more informed target selection and earlier confidence in development decisions.
- Together, the companies aim to impose greater biological rigor on early CNS drug development, reflecting a broader industry shift toward data-driven validation of complex, intracellular therapeutic strategies rather than symptom-focused approaches.
Nxera Pharma Regains Full Rights to Phase 2–Ready GPR52 Program in Schizophrenia
Pulse:
- Nxera Pharma regained full global rights to its GPR52 agonist program after Boehringer Ingelheim declined to exercise its licensing option.
- The lead compound, NXE’149, has demonstrated a favorable Phase 1 safety profile and evidence of CNS target engagement across cognitive and neurophysiological endpoints.
- GPR52 expression spans brain regions linked to positive, negative, and cognitive symptoms, offering potential differentiation from existing antipsychotics.
- Nxera plans to pursue new partnering discussions in 2026, reframing the outcome as a strategic reset rather than a clinical setback.
Syremis Therapeutics Launches With $165M to Build Reference Drugs for Mental Health Disorders
Pulse:
- Syremis Therapeutics formally launched operations backed by a $165 million Series A round co-led by Dexcel Pharma and Third Rock Ventures, immediately placing it among the most highly capitalized new CNS-focused biotechs in recent years.
- The company is advancing ST-905, a potent M1/M4 muscarinic agonist currently in Phase 1 development, reflecting renewed industry confidence in muscarinic modulation following recent clinical validation in schizophrenia and other psychiatric disorders.
- A second program, ST-901, a novel NMDA receptor antagonist, is progressing through IND-enabling studies, with first-in-human trials planned for next year, expanding Syremis’ reach across both cholinergic and glutamatergic pathways.
- The launch strategy emphasizes “reference drugs” grounded in well-validated neuropsychiatric biology, signaling a shift away from high-risk novelty toward clinically de-risked mechanisms with clearer regulatory and commercial pathways.
Amphix Bio Raises $12.5M Seed Round to Advance Supramolecular Peptide Platform
Pulse:
- Amphix Bio has closed a $12.5 million seed financing round to advance its supramolecular therapeutic peptide (STP) platform toward human clinical trials, bringing the total funding to $18 million, including non-dilutive capital.
- The platform leverages self-assembling peptide nanostructures designed to activate cell receptors more potently than conventional drugs, with applications across neurological injury, neurodegeneration, and inflammatory conditions.
- Lead candidate AMFX-200 has already secured Orphan Drug Designation for acute spinal cord injury, while a second program, AMFX-100, received FDA Breakthrough Device Designation for degenerative disc disease.
- The raise underscores growing investor appetite for platform technologies that combine regenerative biology with regulatory momentum in high-unmet-need neurological indications.
Rosalind Franklin University Secures $1.7M NIH Grant for Social Recognition Research
Pulse:
- Rosalind Franklin University received $1.7 million in NIH funding to investigate neural mechanisms underlying social recognition deficits in schizophrenia and autism spectrum disorders.
- The research focuses on oxytocin signaling within the supramammillary nucleus, a key but underexplored brain region involved in social memory.
- Conducted in collaboration with Mount Sinai, the study aims to identify new therapeutic targets for core social impairments rather than peripheral symptoms.
- The award highlights continued federal investment in circuit-level neuroscience with translational relevance for psychiatric disease.
NeuraWorx Closes Oversubscribed Seed Round to Advance Cerebrovascular Pacing in CNS Disorders
Pulse:
- NeuraWorx Medical Technology closed an oversubscribed seed round led by Nexus NeuroTech Ventures to advance its Cerebrovascular Pacing System™, a first-in-class bioelectronic platform targeting brain fluid dynamics.
- The company’s approach focuses on restoring cerebrovascular and glymphatic function, mechanisms increasingly implicated in neurodegenerative and neuropsychiatric diseases but historically underserved by device innovation.
- Investors highlighted the strength of NeuraWorx’s mechanistic hypothesis, biomarker-driven development strategy, and emerging clinical evidence supporting translatability.
- The financing enables team expansion and acceleration toward a formal clinical and regulatory pathway, reinforcing momentum in next-generation neuromodulation beyond traditional neural stimulation targets.
Bracco Secures Positive CHMP Opinion for Vueway MRI Contrast Use in Infants
Pulse:
- The EMA’s CHMP adopted a positive opinion supporting the use of Vueway® (gadopiclenol) in pediatric patients from birth, extending its approved indication to infants under two years of age.
- Vueway is a highly stable macrocyclic gadolinium-based contrast agent with high relaxivity, enabling diagnostic-quality imaging at half the gadolinium dose of standard agents.
- Reduced gadolinium exposure is particularly critical in neonates and infants, where long-term tissue retention remains a concern.
- The decision reinforces regulatory confidence in next-generation imaging agents that balance diagnostic performance with improved safety profiles.
Psyence BioMed Clears Regulatory Milestone for Phase IIb Psilocybin Trial
Pulse:
- Psyence BioMed received ethics committee approval to use PsyLabs’ GMP-grade psilocybin product in its ongoing Phase IIb trial for adjustment disorder in cancer patients.
- The approval strengthens Psyence’s vertically integrated model, spanning botanical sourcing, API manufacturing, and clinical execution.
- The randomized, controlled study will evaluate two therapeutic doses combined with structured psychotherapy, with top-line results expected in 2026.
- The milestone underscores growing regulatory normalization of psychedelic-assisted therapies within controlled clinical frameworks.
Curasight Doses First Patient in Phase 1 uTREAT Trial for Glioblastoma
Pulse:
- Curasight successfully dosed the first patient in its Phase 1 clinical trial evaluating uTREAT®, a targeted radiopharmaceutical therapy for high-grade gliomas, including glioblastoma.
- The trial marks the first clinical entry of uTREAT and positions Curasight as a clinical-stage company across both its therapeutic and diagnostic theranostic platforms.
- uTREAT targets the uPAR receptor and is designed to deliver localized radiation directly to tumor tissue, potentially reducing reliance on external beam radiation and limiting damage to healthy brain tissue.
- Early dosing was completed without reported safety issues, representing a critical milestone in addressing one of neuro-oncology’s most lethal and treatment-resistant cancers.
NeuExcell Reports Encouraging First-in-Human Results for In Situ Conversion Gene Therapy in Glioma
Pulse:
- NeuExcell Therapeutics reported encouraging clinical data for NXL-004, the world’s first in situ conversion gene therapy for malignant glioma, presented at ESMO Asia 2025.
- The therapy uses an AAV vector to deliver NeuroD1 directly into tumor cells, reprogramming them into non-dividing neurons or triggering apoptosis, representing a fundamentally new treatment paradigm.
- In a small first-in-human study, treated patients demonstrated median overall survival exceeding 12 months, with one patient achieving a complete radiographic response.
- The data support further development of in situ cellular reprogramming as a novel approach for both brain cancer and broader neurodegenerative indications.
Annovis to Launch Open-Label Extension Study of Buntanetap in Parkinson’s Disease
Pulse:
- Annovis announced plans to initiate a 36-month open-label extension study of buntanetap in Parkinson’s disease, enrolling up to 500 patients beginning in January 2026.
- The study will include both prior trial participants and patients receiving deep brain stimulation, a population often excluded from clinical research.
- Long-term safety, durability of clinical benefit, and biomarker outcomes will be assessed, supporting Annovis’ disease-modifying positioning for buntanetap.
- The extension study strengthens Annovis’ readiness for a future NDA by helping meet FDA exposure requirements across its Parkinson’s and Alzheimer’s programs.
Yesterday’s NeuroPulse highlighted the most important developments across neuroscience research, clinical execution, regulatory action, and capital flows.
